CCN3 promotes prostate cancer bone metastasis by modulating the tumor-bone microenvironment through RANKL-dependent pathway

Carcinogenesis

Volumn 34, Issue 7, 2013, Pages 1669-1679

  Chen, Po Chun ^a   Cheng, Hsu Chen ^a   Tang, Chih Hsin ^b,c,d  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; BETA INTEGRIN; FOCAL ADHESION KINASE; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE B;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER STAGING; CELL FUNCTION; CELL MIGRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; BONE NEOPLASMS; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CULTURE MEDIA, CONDITIONED; HUMANS; MALE; MICE; MICE, SCID; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; NF-KAPPA B; OSTEOCLASTS; PROSTATIC NEOPLASMS; RANK LIGAND; RATS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84880301279     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt103     Document Type: Article

References (45)

1. Bryant, R.J. et al. (2008) Screening for prostate cancer: an update. Eur. Urol., 53, 37-44.
2. Shah, R.B. et al. (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res., 64, 9209-9216.
3. Keller, E.T. et al. (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J. Cell. Biochem., 91, 718-729.
4. Roudier, M.P. et al. (2003) Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum. Pathol., 34, 646-653.
5. Carlin, B.I. et al. (2000) The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer, 88, 2989-2994.
6. Roodman, G.D. (2004) Mechanisms of bone metastasis. Discov. Med., 4, 144-148.
7. Hung, T.T. et al. (2011) Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model. PLoS One, 6, e19389.
8. Lipton, A. et al. (2002) The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest., 20 (suppl. 2), 45-54.
9. Asahi, H. et al. (2003) Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis. J. Urol., 169, 281-282.
10. Machado, M. et al. (2009) Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials. Clin. Ther., 31, 962-979.
11. Stopeck, A.T. et al. (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol., 28, 5132-5139.
12. Lu, Y. et al. (2007) Monocyte chemotactic protein-1 mediates prostate cancer- induced bone resorption. Cancer Res., 67, 3646-3653.
13. Hwang, Y.S. et al. (2012) Secretion of IL-6 and IL-8 from lysophosphatidic acid-stimulated oral squamous cell carcinoma promotes osteoclastogenesis and bone resorption. Oral Oncol., 48, 40-48.
14. Joliot, V. et al. (1992) Proviral rearrangements and overexpression of a new cellular gene (nov) in myeloblastosis-associated virus type 1-induced nephroblastomas. Mol. Cell. Biol., 12, 10-21.
15. Planque, N. et al. (2003) A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int., 3, 15.
16. Chen, C.C. et al. (2009) Functions and mechanisms of action of CCN matricellular proteins. Int. J. Biochem. Cell Biol., 41, 771-783.
17. Perbal, B. et al. (2008) Prognostic value of CCN3 in osteosarcoma. Clin. Cancer Res., 14, 701-709.
18. Perbal, B. et al. (2009) Prognostic relevance of CCN3 in Ewing sarcoma. Hum. Pathol., 40, 1479-1486.
19. Fukunaga-Kalabis, M. et al. (2008) Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene, 27, 2552-2560.
20. Yang, W. et al. (2011) Impact of CCN3 (NOV) glycosylation on migration/invasion properties and cell growth of the choriocarcinoma cell line Jeg3. Hum. Reprod., 26, 2850-2860.
21. Huang, C.Y. et al. (2011) Nephroblastoma overexpressed gene (NOV) enhances cell motility and COX-2 upregulation of human osteosarcoma involves avß5 integrin, ILK and AP-1-dependent pathways. Biochem. Pharmacol., 81, 577-585.
22. Maillard, M. et al. (2001) Differential expression of the ccn3 (nov) protooncogene in human prostate cell lines and tissues. Mol. Pathol., 54, 275-280.
23. Chen, P.C. et al. (2012) CCN3 increases cell motility and ICAM-1 expression in prostate cancer cells. Carcinogenesis, 33, 937-945.
24. Tang, C.H. et al. (2007) Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J. Biol. Chem., 282, 2346-2354.
25. Cai, Z. et al. (2009) Monocyte chemotactic protein 1 promotes lung cancerinduced bone resorptive lesions in vivo. Neoplasia, 11, 228-236.
26. Zhang, J. et al. (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest., 107, 1235-1244.
27. Cappellen, D. et al. (2002) Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. J. Biol. Chem., 277, 21971-21982.
28. Tzeng, H.E. et al. (2011) CCN3 increases cell motility and MMP-13 expression in human chondrosarcoma through integrin-dependent pathway. J. Cell. Physiol., 226, 3181-3189.
29. Logothetis, C.J. et al. (2005) Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer, 5, 21-28.
30. Dougall, W.C. et al. (2006) The RANK/RANKL/OPG triad in cancerinduced bone diseases. Cancer Metastasis Rev., 25, 541-549.
31. Wittrant, Y. et al. (2004) RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim. Biophys. Acta, 1704, 49-57.
32. Mundy, G.R. (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer, 2, 584-593.
33. McCallum, L. et al. (2009) CCN3-a key regulator of the hematopoietic compartment. Blood Rev., 23, 79-85.
34. Taichman, R.S. et al. (2007) The evolving biology and treatment of prostate cancer. J. Clin. Invest., 117, 2351-2361.
35. Pienta, K.J. et al. (2005) The "emigration, migration, and immigration" of prostate cancer. Clin. Prostate Cancer, 4, 24-30.
36. Zhang, J. et al. (2003) Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res., 63, 7883-7890.
37. Morrissey, C. et al. (2007) Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases. BMC Cancer, 7, 148.
38. Nakagawa, N. et al. (1998) RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun., 253, 395-400.
39. Lorusso, G. et al. (2008) The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol., 130, 1091-1103.
40. Ooi, L.L. et al. (2011) The bone remodeling environment is a factor in breast cancer bone metastasis. Bone, 48, 66-70.
41. Khosla, S. (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology, 142, 5050-5055.
42. Katsuki, Y. et al. (2008) Inhibitory effect of CT domain of CCN3/NOV on proliferation and differentiation of osteogenic mesenchymal stem cells, Kusa-A1. Biochem. Biophys. Res. Commun., 368, 808-814.
43. Ouellet, V. et al. (2012) CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis. J. Cell Commun. Signal., 6, 73-85.
44. Dornhofer, N. et al. (2006) Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res., 66, 5816-5827.
45. Aikawa, T. et al. (2006) Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol. Cancer Ther., 5, 1108-1116.